2 withdrawn. 2 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Withdrawn 2 |
| Phase 1 | 1 | Withdrawn 1 |
Follow Progesterone Receptor Negative: new trials by email Literature Review of Progesterone Receptor Negative trials Research Report on Progesterone Receptor Negative
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Effect of Pembrolizumab and Cisplatin on Metastatic, Locally Recurrent or Inoperable Triple-Negative Breast Cancer Pembrolizumab, Cisplatin - Estrogen Receptor Negative, HER2/Neu Negative | Phase 2 | Withdrawn | University of Washington | 2019-04-01 | 2019-04-26 | |
| Glembatumumab Vedotin, Nivolumab, and Ipilimumab in Treating Patients With Advanced Metastatic Solid Tumors That Cannot Be Removed by Surgery Glembatumumab Vedotin, Ipilimumab, Laboratory Biomarker Analysis - Advanced Malignant Solid Neoplasm, Estrogen Receptor Negative | Phase 1 / Phase 2 | Withdrawn | National Cancer Institute (NCI) | 2018-04-20 | 2018-07-18 |
Breast Neoplasms (2) · Triple Negative Breast Neoplasms (2) · Melanoma (1) · Neoplasm Metastasis (1) · Uveal Melanoma (1)
Breast Diseases (2) · Neoplasms (2) · Neoplasms by Site (2) · Skin Diseases (2) · Skin and Connective Tissue Diseases (2) · Eye Diseases (1) · Eye Neoplasms (1) · Neoplasms by Histologic Type (1) · Neoplasms, Germ Cell and Embryonal (1) · Neoplasms, Nerve Tissue (1) · Neoplastic Processes (1) · Neuroectodermal Tumors (1) · Neuroendocrine Tumors (1) · Nevi and Melanomas (1) · Pathologic Processes (1)
CR011-vcMMAE (1) · CTLA-4 Antigen (1) · Cisplatin (1) · Immunoglobulin G (1) · Ipilimumab (1) · Nivolumab (1) · glembatumumab vedotin (1) · pembrolizumab (1)
National Cancer Institute (NCI) (1) · University of Washington (1)
United States (1)
Haeseong Park (1) · Jennifer Specht, MD (1)
UM1CA186704 (1)